[ad_1]
January 14, 2021
1 min read
Source / Disclosures
Disclosures: Joyner reports links with the Biomedical Advanced Research and Development Authority, the Mayo Clinic, the Schwab Charitable Fund, the United Health Group, the National Basketball Association, and the Millennium Pharmaceuticals Octapharma USA, Inc., and grants from the National Heart, Lunch and Blood Institute during the study. Please see the study for relevant financial information from all other authors.
Among hospitalized patients with COVID-19 who were not on mechanical ventilation, receiving high titer convalescent plasma was associated with a lower risk of death than receiving plasma with lower antibody levels, reported Researchers.
“In response to the coronavirus pandemic, the Mayo Clinic launched – with the support and direction of the Biomedical Advances Research and Development Authority and the FDA – the U.S. Extended Access Program for Convalescent Plasma to provide a access and assess the safety profile of this therapy experience, “ Michael J. Joyner, MARYLAND, Mayo Clinic anesthesiologist, explained to Healio.
Michael J. Joyner
Joyner and colleagues conducted a retrospective study using the Expanded Access Program registry to determine levels of anti-SARS-CoV-2 immunoglobulin G antibodies in convalescent plasma used to treat hospitalized adults with COVID- 19. They assessed patients who had measured anti-SARS-CoV-2 antibody levels and 30-day mortality data available through July 4. According to the study, the main outcome was death within 30 days of plasma transfusion.
Of the 3,082 patients included in their analysis, 115 out of 515 (22.3%) patients in the high titer group, 549 out of 2,006 patients (27.4%) in the medium titer group and 166 out of 561 patients (29 , 6%) in the low-titer group -title group died within 30 days of plasma transfusion, Joyner and colleagues reported.
They observed a lower risk of death within 30 days in the high titer group compared to the low titer group in patients who did not receive mechanical ventilation prior to transfusion (RR = 0.66; 95 CI %, 0.48-0.91), but no effect among patients who received mechanical ventilation (RR = 1.02; 95% CI, 0.78-1.32)
“Plasma transfusion that had higher levels of anti-SARS-CoV-2 IgG antibody was associated with lower mortality than plasma transfusion with lower antibody levels,” Joyner said. “Patients who received plasma within 3 days of diagnosis had lower mortality than those transfused later in the course of the disease.”
COVID-19 Resource Center
Source link
